This is an international Web site for Signifor® (pasireotide) and is intended for healthcare professionals outside the US. The information on the site is not country specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country.

Signifor Information for International Healthcare Professionals Signifor Information for US residents Signifor Information for Patients Outside the US

Summary of Product Characteristics Patient Leaflet Safety Information AAA | Print | Share

U.S. RESIDENTS | This site is intended for healthcare professionals outside the US.

English Español

MOA|Trial Design|Efficacy|Safety|Dosing and Adminstration

HOME ABOUT SIGNIFOR Dosing and Adminstration

The Dosing and Administration of Signifor

The recommended initial dose of Signifor is 0.6 mg, self-administered by subcutaneous injection twice daily.1

Signifor Dosing and Adminstration

Continue Signifor for as long as clinical benefit is derived.1

Dose reduction recommendations

Signifor is filled in a snap-off ampoule, containing a clear, colourless, 1-mL solution.1

Solution mL

Recommended storage for Signifor

Reference: 1. Signifor Summary of Product Characteristics. Novartis Pharma AG.
Disclaimer: This is an international Web site for Signifor® (pasireotide) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country specific and may contain information that is outside the approved indications in the country in which you are located.
Novartis Oncology

About Novartis Oncology Contact Us Site Map Use of Web site is governed by the Terms of Use and Privacy Policy
© Novartis AG